Introduction
============

The incidence of cardiovascular events is higher in coronary artery disease patients (CAD) with type 2 diabetes (T2D) than in CAD patients without T2D (Haffner et al., [@B15]; Junttila et al., [@B23]), but the physiological or pathophysiological mechanisms causing these differences are not well known. Altered autonomic regulation is one potential mechanism resulting in the increased number of cardiovascular events in CAD + T2D patients (Okada et al., [@B37]; Pop-Busui et al., [@B42]; Lanza et al., [@B28]). Autonomic regulation can be studied using various methods at the laboratory, or ambulatory condition tests such as passive head-up tilt and handgrip tests (Montano et al., [@B34]; Tulppo et al., [@B51], [@B53]; Fu et al., [@B10]), or ambulatory heart rate (HR) variability and blood pressure measurements (Pagani et al., [@B39]; Kleiger et al., [@B26]; Piira et al., [@B41]). Analysis of autonomic regulation during and after exercise has also been used in various physiological (Yamamoto et al., [@B61]; Gregoire et al., [@B13]; Tulppo et al., [@B56], [@B55]) and clinical settings (Cole et al., [@B6], [@B7]; Jouven and Ducimetiere, [@B21]; Jouven et al., [@B22]; Kiviniemi et al., [@B25]).

There is increasing evidence that the recovery phase after exercise is a vulnerable phase for various cardiovascular events. Case-crossover studies have shown that exercise as a trigger of acute myocardial infarction is not limited to the time of exercise, but extends for a certain time period after cessation of physical activity (Siscovick et al., [@B48], [@B47]; Albert et al., [@B1]; von Klot et al., [@B57]). Similarly, the risk of sudden cardiac death is transiently increased in the 30-min after vigorous exercise, and atrial fibrillation episodes occur more commonly after rather than before exercise (Siscovick et al., [@B48], [@B47]; Coumel, [@B8]; Albert et al., [@B1]; Huikuri, [@B16]). Measurement of autonomic function in the very early phase of recovery after exercise has also provided prognostic information. For example, delayed HR recovery 1--2 min after exercise has been shown to predict cardiovascular events in the general population and in various patient groups and animal studies (Cole et al., [@B6]; Lauer and Froelicher, [@B29]; Nissinen et al., [@B36]; Jouven et al., [@B22]; Smith et al., [@B49]). Recently, we have shown that co-activation of both autonomic arms may occur during the recovery phase of exercise (Tulppo et al., [@B52]), which may partly explain the clustering of various cardiovascular events in the recovery phase of exercise.

The present research was designed to study the behavior of HR dynamics during exercise and in the recovery phase of exercise in CAD patients with and without T2D, matched for age, ejection fraction (EF), and sex. We hypothesized that autonomic regulation, measured by HR recovery and HR variability methods, differs in CAD patients with and without T2D, particularly during post-exercise condition.

Materials and Methods
=====================

Subjects and study protocol
---------------------------

The present study was conducted in the Department of Exercise and Medical Physiology at Verve (Oulu, Finland) and Oulu University Hospital, and the patients were selected from patients in the ARTEMIS (Innovation to Reduce Cardiovascular Complications of Diabetes at the Intersection) study database who had stable CAD without (*n* = 64) and with T2D (*n* = 68). The exclusion criteria were inability to perform the exercise stress test, unstable angina at the time of recruitment, advanced age (\>75 years), a recent (\<6 months) myocardial infarction, severe nephropathy, heart failure, scheduled cardiac revascularization therapy, T2D diagnosed less than 6 months from the beginning of study, diabetes autonomic neuropathy, dementia, alcoholism, drug abuse, or any condition that could impair the subject's capacity to give informed consent. CAD was documented by coronary angiography and T2D was verified by oral glucose tolerance test according to current recommendations (WHO, [@B58]). The study was performed according to the Declaration of Helsinki, the local committees of research ethics in the Northern Ostrobothnia Hospital District (Oulu, Finland) approved the protocol, and all the subjects gave written informed consent.

The laboratory measurements were performed in the Department of Exercise and Medical Physiology at Verve (Oulu, Finland). The patients were not allowed to eat or consume caffeine for 3 h before the tests. Physical exercise and use of alcohol were prohibited for 24 h before testing. Electrocardiography (ECG) and R--R intervals were collected for 10 min at supine rest, during exercise, and 10 min after exercise in supine position. Breathing was spontaneous in all phases. A capillary blood sample was obtained for analysis of HbA1c concentration before testing (Afinion™ AS100, Axis-Shield PoC AS, Oslo, Norway).

Exercise stress test
--------------------

The patients performed an incremental maximal test on a bicycle ergometer (Monark Ergomedic 839 E; Monark Exercise AB, Vansbro, Sweden), starting at 30 W with the work rate increasing at a rate of 10 and 15 W every 1 min until exhaustion for females and males, respectively. The patients moved to the supine position within 30 s after cessation of exercise. The patients were not allowed to move or talk during the recovery phase.

Ventilation (*V~E~*) and gas exchange (M909 Ergospirometer, Medikro, Kuopio, Finland) were measured and reported as the mean value for every minute. The highest 1-min mean value of oxygen consumption was expressed as the peak oxygen consumption (VO~2peak~). Maximal workload (W) and maximal METs were calculated as average workload and METs during the last 1 min of the test. ECG was monitored and recorded using a standard 12-lead ECG (GE Healthcare, Cam-14, Waukesha, WI, USA) and at the same time R--R intervals were recorded with a Polar R--R recorder with a sampling frequency of 1,000 Hz (Polar Electro, Kempele, Finland). Blood pressure was measured with an electronic sphygmomanometer (Tango, Sun-Tech, Raleigh, NC, USA) at rest and during exercise testing. The patients were encouraged to reach a symptom-limited maximal workload, and exercise was stopped if ST depression was \>0.2 mV.

The maximal HR was calculated as a mean value of 5 R--R intervals before cessation of exercise from Polar R--R interval data and converted to maximal HR in beats/min with the following equation: maximal HR (beats/min) = 60·(mean R--R interval in ms/1000)^−1^. The chronotropic response to exercise was calculated by chronotropic response index (CRI) with the following equation: CRI = 100·(maximal HR − resting HR)·(220 − age − resting HR)^−1^ (Kiviniemi et al., [@B25]), and HR reserve as maximal HR − resting HR. HR recovery values were calculated as mean values of 5 R--R intervals around the time points of 15 (HRR~15~), 30 (HRR~30~), 60 (HRR~60~), and 120 (HRR~120~) s after cessation of exercise from Polar data. Thereafter, HR recovery (beats/min) was calculated as the change in HR from maximal HR to recovery HR at the time points of 15, 30, 60, and 120 s after cessation of exercise. The slope of HR during the 60-s after cessation of exercise (HRR~slope~) was calculated by linear model using above described HR values at the maximum and 15, 30, and 60 s time points (Figure [1](#F1){ref-type="fig"}).

![**Example of heart rate recovery as the slope of heart rate during the first 60 s after cessation of exercise for two patients (with and without type 2 diabetes) with similar age and maximal heart rate**. The slope was calculated by linear model using mean values of 5 R--R intervals \[converted to the HR values in beats/min as 60·(mean R--R interval in ms/100)^−1^\] at maximum and around the time points of 15, 30, and 60 s after cessation of exercise.](fphys-02-00057-g001){#F1}

Heart rate variability
----------------------

R--R intervals were analyzed from the last 5-min period at rest, at every load during exercise (1-min periods), and from 3 to 8 min (5-min) after exercise. Before HR variability analysis (using Polar R--R data), all of the R--R intervals were edited manually to exclude all premature beats and noise, which accounted for \<8% in every subject. ECG data was used during the editing to confirm sinus origin of the beats. An autoregressive model was used to estimate the power spectrum densities of HR variability after period level detrending (Huikuri et al., [@B18]; Tulppo et al., [@B56]). The power spectra were quantified by measuring the area under two frequency bands: LF power (0.04--0.15 Hz) and HF power (0.15--0.4 Hz). Details of the spectrum analyses have been described previously elsewhere (Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, [@B50]). Detrended fluctuation analysis (DFA) method was used to calculate fractal-like correlation properties of the R--R interval data (Peng et al., [@B40]; Iyengar et al., [@B20]). In this study the short-term (4--11 beats) scaling exponent (α-1) was calculated based on previous experiments (Mäkikallio et al., [@B31]).

Statistics
----------

The data were presented as mean ± SD. The normal Gaussian distribution of the data was verified with the Kolmogorov--Smirnov goodness-of-fit test (*z* value \> 1.0). For repeated measurements of post-exercise HR recovery (HRR~15~, HRR~30~, HRR~60~, HRR~120~), two-factor ANOVA (time × group) was used to assess main effects followed by *post hoc* comparison (unpaired *t*-test). Significant *post hoc* differences in HR recovery between the groups were adjusted for maximal METs, BMI, and medications (calcium antagonists and nitrates) using ANCOVA. For other variables, the unpaired Student's *t*-test was used to assess the differences between CAD and CAD + T2D groups in normally distributed data. The Mann--Whitney *U*-test was used to assess the difference in HR variability indices between groups. The Chi-square test was used for categorical variables. The data were analyzed using SPSS software (SPSS 19.0, SPSS Inc., Chicago, USA). A *p*-value \< 0.05 was considered statistically significant.

Results
=======

Study population
----------------

The characteristics of the study population, including comparisons between diabetic and non-diabetic patients, are given in Table [1](#T1){ref-type="table"}. The diabetic patients' body composition, e.g., weight (*p* \< 0.001), waist circumference (*p* \< 0.001), BMI (*p* \< 0.001), and HbA1c (*p* \< 0.001) differed from that of the non-diabetic patients. However, blood pressure, EF, history of infarction, and revascularization or smoking did not differ between the diabetic and non-diabetic patients (Table [1](#T1){ref-type="table"}). Medication did not differ between the groups, except that calcium antagonists, nitrates, and antidiabetics were more common among the diabetic than the non-diabetic patients (Table [1](#T1){ref-type="table"}).

###### 

**Characteristics of patients**.

                          CAD + T2D (*n* = 68)   CAD (*n* = 64)   *p*-Level
  ----------------------- ---------------------- ---------------- --------------
  Sex (F/M)               15/53                  13/51            *p* = 0.488
  Age (years)             61 ± 5                 62 ± 5           *p* = 0.514
  Height (cm)             171 ± 7                171 ± 8          *p* = 0.678
  Weight (kg)             89 ± 15                80 ± 12          *p* \< 0.001
  Waist (cm)              105 ± 12               94 ± 10          *p* \< 0.001
  Hip (cm)                105 ± 10               99 ± 6           *p* \< 0.001
  Waist/Hip ratio         1.00 ± 0.07            0.95 ± 0.07      *p* \< 0.001
  BMI (kg m^−2^)          30 ± 4                 27 ± 3           *p* \< 0.001
  HbA1c (%)               6.0 ± 0.7              5.5 ± 0.2        *p* \< 0.001
  SBP (mmHg)              138 ± 18               136 ± 16         *p* = 0.672
  DBP (mmHg)              82 ± 10                82 ± 8           *p* = 0.875
  **HISTORY OF AMI**                                              
  NSTEMI                  18 (26%)               19 (30%)         *P* = 0.469
  STEMI                   13 (19%)               14 (21%)         *p* = 0.662
  **REVASCULARIZATION**                                           
  CAGB                    14 (21%)               13 (28%)         *p* = 0.506
  PCI                     42 (67%)               27 (59%)         *p* = 0.426
  Current smokers         3 (4%)                 8 (12%)          *p* = 0.147
  LVEF (%)                67 ± 8                 65 ± 8           *p* = 0.107
  **MEDICATION**                                                  
  Anticougulants          66 (97%)               63 (98%)         *p* = 1.000
  Beta blockers           68 (100%)              64 (100%)        *p* = 1.000
  Calcium antagonists     20 (29%)               9 (14%)          *p* = 0.037
  ACEI                    31 (46%)               23 (36%)         *p* = 0.291
  AT2                     13 (19%)               14 (22%)         *p* = 0.830
  Diuretics               26 (38%)               15 (23%)         *p* = 0.090
  Statin                  63 (93%)               57 (89%)         *p* = 0.553
  Insulines               10 (7%)                0 (0%)           *p* = 0.001
  Oral antidiabetics      50 (74%)               0 (0%)           *p* \< 0.001
  Nitrates                28 (41%)               8 (13%)          *p* \< 0.001
  Arrhythmia              1 (1%)                 1 (1%)           *p* = 1.000

*Values are mean ± SD. BMI, body mass index; HbA1c, Glycosylated hemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; AMI, acute myocardial infarction; NSTEMI, no-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction; revascularized, the patients who had at least one of the procedures (CABG, coronary artery by-pass grafting or PCI, Percutaneus coronary intervention); LVEF, left ventricular ejection fraction; ACEI, angiotensin conversion enzyme inhibitor; AT2, angiotensin II receptor blocker; CAD, coronary artery disease group; CAD + T2D, coronary artery disease with type 2 diabetes*.

HR response to maximal exercise
-------------------------------

The results of the maximal exercise test, including comparisons between diabetic and non-diabetic patients, are given in Table [2](#T2){ref-type="table"}. Maximal exercise capacity was lower (*p* \< 0.001) in the diabetes patients, but maximal HR (*p* = 0.178) was at the same level compared with the non-diabetic patients (Table [2](#T2){ref-type="table"}). HR reserve was smaller (*p* = 0.027) and CRI tended to be smaller (*p* = 0.057) in the diabetic patients than in the non-diabetic patients. However, there were not significant differences between groups in HR reserve or CRI after adjustment for maximal METs, BMI, and medication, e.g., for HR reserve ANCOVA *p* = 0.686, *p* \< 0.001, *p* = 0.126, and *p* = 0.169 for diabetes, Mets, BMI, and calcium antagonists, respectively. There was no difference between the groups in the prevalence of ST segment depression \>0.1 mV during the exercise test.

###### 

**Maximal exercise capacity and heart rate recovery**.

                              CAD + T2D (*n* = 68)   CAD (*n* = 64)   *p*-Level
  --------------------------- ---------------------- ---------------- --------------
  Max load (W)                139 ± 41               155 ± 43         *p* = 0.033
  Max METs                    6.5 ± 1.7              7.7 ± 1.9        *p* \< 0.001
  **MAX VO2PEAK**                                                     
  ml kg^−1^ min^−1^           21.6 ± 5.8             25.9 ± 6.5       *p* \< 0.001
  l min^−1^                   1.89 ± 0.52            2.05 ± 0.58      *p* = 0.101
  Max ST depression \> 1 mm   32 (47%)               57 (49%)         *p* = 0.228
  Max HR (bpm)                128 ± 19               132 ± 18         *p* = 0.178
  HR reserve (bpm)            70 ± 20                78 ± 18          *p* = 0.027
  CRI (bpm)                   69 ± 18                75 ± 17          *p* = 0.057
  **HR RECOVERY**                                                     
  15 s (bpm)                  10.9 ± 4.6             10.8 ± 5.0       *p* = 0.376
  30 s (bpm)                  15.8 ± 7.0             17.8 ± 6.9       *p* = 0.098
  60 s (bpm)                  32.7 ± 10.5            37.8 ± 9.7       *p* = 0.006
  120 s (bpm)                 44.3 ± 13.4            48.9 ± 11.1      *p* = 0.037
  Slope 60 (beats/s)          −0.53 ± 0.17           −0.62 ± 0.14     *p* = 0.004

*Values are mean ± SD. METs, metabolic equivalents; VO~2~peak, peak uptake oxygen; HR, heart rate; CRI, maximal chronotropic response index*.

HR recovery
-----------

Type 2 diabetes modified post-exercise HR recovery (main effect for time × group interaction *p* = 0.037). The diabetic patients had delayed HRR~60~ (*p* = 0.006), HRR~120~ (*p* = 0.037), and HRR~slope~ (*p* = 0.004) compared with the non-diabetic patients (Table [2](#T2){ref-type="table"}). However, there were not significant differences between groups in HRR~60~, HRR~120~, or HRR~slope~ after adjustment for maximal METs, BMI, and medication, e.g., for HRR~60~ ANCOVA *p* = 0.223, *p* = 0.061, *p* = 0.387, and *p* = 0.094 for diabetes, Mets, BMI, and calcium antagonists, respectively. The corresponding *p* values for HRR~120~ were *p* = 0.980, *p* = 0.001, *p* = 0.451, and *p* = 0.006 and for HRR~slope~ *p* = 0.228, *p* = 0.030, *p* = 0.404, and *p* = 0.079 for diabetes, Mets, BMI, and calcium antagonists, respectively. Nitrates did not modify HR behavior between groups at any condition. Examples of HRR~slope~ for non-diabetic and diabetic subjects are shown in Figure [1](#F1){ref-type="fig"}.

HR and HR variability at rest, during submaximal exercise and after exercise
----------------------------------------------------------------------------

Heart rate and HR variability before and after exercise, including comparisons between diabetic and non-diabetic patients, are given in Table [3](#T3){ref-type="table"}. Five diabetic patients were excluded from the analysis due to the significant number of extra systoles or technical artifacts in the R--R interval data. One non-diabetic patient was excluded due to the extra systoles in both pre- and post-exercise conditions and one in post-exercise condition due to the same reason.

###### 

**Average values of linear and non-linear heart rate variability before exercise (5 min) and in post-exercise condition from 3 to 8 min after exercise, both in supine position**.

                            CAD + T2D      CAD            *p*-Level
  ------------------------- -------------- -------------- -------------
  **Pre-exercise 5 min**    ***n* = 63**   ***n* = 63**   
  HR (bpm)                  57 ± 10        54 ± 6         *p* = 0.030
  SDNN (ms)                 36 ± 19        36 ± 21        *p* = 0.969
  HF power (ms^2^)          299 ± 353      479 ± 1347     *p* = 0.490
  LF power (ms^2^)          385 ± 521      409 ± 563      *p* = 0.940
  LF/HF ratio               1.81 ± 1.71    1.47 ± 1.34    *p* = 0.210
  α-1                       1.04 ± 0.27    0.99 ± 0.26    *p* = 0.280
  **Post-exercise 5 min**   ***n* = 63**   ***n* = 62**   
  HR (bpm)                  76 ± 10        75 ± 10        *p* = 0.765
  SDNN (ms)                 29 ± 12        28 ± 17        *p* = 0.386
  HF power (ms^2^)          102 ± 172      114 ± 246      *p* = 0.268
  LF power (ms^2^)          162 ± 212      175 ± 352      *p* = 0.608
  LF/HF ratio               2.8 ± 2.3      3.9 ± 3.9      *p* = 0.257
  α-1                       1.18 ± 0.30    1.24 ± 0.28    *p* = 0.277

*Values are mean ± SD. HR, heart rate; SDNN, SD of normal-to-normal R--R intervals; HF, high frequency power of R--R intervals; LF, low frequency power of R--R intervals; α-1, fractal scaling exponent of R--R intervals*.

The diabetic patients had a higher HR in resting condition than the non-diabetic patients (*p* = 0.030), but no other differences were observed at rest or in post-exercise condition (Table [3](#T3){ref-type="table"}). HR or HR variability did not differ between the groups during submaximal exercise at the levels of 40, 60, or 80% of maximal oxygen uptake, e.g., HR was 92 ± 12 vs. 95 ± 14 bpm (*p* = 0.099) and α~1~ 1.02 ± 0.37 vs. 1.02 ± 0.32 (*p* = 0.93) at the level of 61 ± 5% and 61 ± 5% of maximal oxygen uptake for diabetic and non-diabetic patients, respectively.

Discussion
==========

The present study showed that post-exercise HR recovery was slower in CAD + T2D patients than in CAD patients, suggesting an impairment of vagal modulation and/or augmented sympathetic activity initially after exercise for diabetic patients. The impaired HR recovery in diabetic patients was the most obvious 1 min after exercise, documented by HRR~60~ and HRR~slope~ indices. However, blunted HR recovery initially after exercise in diabetic patients compared with non-diabetic patients was more closely related to low exercise capacity and obesity than to T2D itself. Taken together, these findings suggest that delayed HR recovery after exercise in T2D patients may be reversible through prevention and treatment, including, e.g., regular exercise and weight management.

Post-exercise HR dynamics
-------------------------

The interplay between sympathetic and vagal regulation of HR during exercise is organized in a reciprocal fashion, i.e., increased sympathetic activity is accompanied by decreased vagal activity in the heart during dynamic exercise (Robinson et al., [@B44]; Maciel et al., [@B30]; Orizio et al., [@B38]; Yamamoto and Hughson, [@B60]; Tulppo et al., [@B56], [@B55]). However, this reciprocal behavior is altered in the recovery phase after exercise due to temporal differences in the recovery pattern of the autonomic arms in post-exercise condition (Tulppo et al., [@B52]). A rapid restoration of vagal activity occurs after cessation of exercise (Imai et al., [@B19]; Goldberger et al., [@B11]; Martinmaki and Rusko, [@B32]; Tulppo et al., [@B52]). On the contrary, the sympathetic nervous system seems to have a longer latency to return to the baseline after cessation of exercise, resulting in long-lasting hyperactivity of sympathetic activity (Ray, [@B43]; Tulppo et al., [@B52]). Taken together, these changes in autonomic regulation may result in dual activation of the sympathetic and vagal arms in post-exercise condition (Tulppo et al., [@B52]). These changes in autonomic activity in post-exercise condition may partly explain the clinical findings, since particularly the recovery phase of exercise has been shown to be a vulnerable phase for various cardiovascular events (Siscovick et al., [@B48], [@B47]; Albert et al., [@B1]; von Klot et al., [@B57]).

It is well known that CAD + T2D patients are at a higher risk for cardiac events than CAD patients without diabetes. Altered autonomic regulation in post-exercise condition is one potential mechanism, since slow HR recovery after exercise has also been associated with cardiovascular events in various clinical and subclinical populations (Cole et al., [@B6]; Lauer and Froelicher, [@B29]; Nissinen et al., [@B36]; Jouven et al., [@B22]). In the present study, HR recovery from 1 to 2 min after exercise was the only marker of autonomic activity separating diabetic and non-diabetic cardiac patients matched with age, sex, and EF all in optimal medications, including β-blockade. Since a complex interaction of autonomic regulation occurs in the initial phase after exercise, it is difficult to detect the difference in HR recovery between diabetic and non-diabetic patients due to impaired vagal activation or augmented sympathetic activation or both. Also circulating catecholamines have an important contribution for the sympathetic post-exercise hyperactivity (Krock and Hartung, [@B27]), but unfortunately we did not measure epinephrine or norepinephrine in the present study. Thirdly, as a novel finding of the present study, there were no differences between patients groups in HR recovery after adjustment for METs and BMI. These findings emphasized regular exercise training and weight management as potential treatments to improve post-exercise HR recovery in CAD + T2D patients. Importantly, also calcium antagonists modified HR recovery particularly 2 min after exercise. Patients with calcium antagonists usually have more severe hypertension which is associated with delayed HR recovery (Carnethon et al., [@B4]).

HR response to maximal exercise
-------------------------------

Measurement of the chronotropic response of HR to exercise has been used to assess particularly sympathetic influence on the heart and it has been shown to be a powerful predictor of cardiac mortality in both asymptomatic populations (Azarbal et al., [@B2]; Gulati et al., [@B14]; Jouven et al., [@B22]; Savonen et al., [@B46]; Kiviniemi et al., [@B25]) and in patients with various cardiac diseases (Myers et al., [@B35]; Savonen et al., [@B45]; Kiviniemi et al., [@B25]). In the present study HR reserve was lower and the maximal chronotropic response adjusted for age (CRI) tended to be lower in CAD + T2D patients than in CAD patients without diabetes. However, there were no differences between patients groups in these indices after adjustment for fitness and BMI.

HR variability
--------------

Type 2 diabetes has been shown to decrease HR variability and baroreflex sensitivity in T2D patients without CAD (Masaoka et al., [@B33]; Frattola et al., [@B9]). There are previous studies where T2D has shown no additional decrease in baroreflex sensitivity among patients with CAD (Wykretowicz et al., [@B59]) or in HR variability among T2D patients with heart failure or CAD (Burger and Aronson, [@B3]; Kiviniemi et al., [@B24]). Also in the present study the short-term HR variability indices measured at resting or post-exercise condition were not able to separate CAD patients with and without T2D. There are several potential explanations for these findings. First, the populations are carefully matched according to age, sex, EF, and β-blockade which all are known to effect on HR variability and may partly explain the present findings. Secondly, short-term HR variability measures at laboratory condition are not so well reproducible than 24-h recordings (Huikuri et al., [@B17]; Tulppo et al., [@B55]) and may be influenced by "white coat" effects in some subjects (Grassi et al., [@B12]). Thirdly, high level of circulating norepinephrine particularly in post-exercise condition may results in abrupt changes in beat-to-beat R--R interval dynamics which are not detected by used HR variability methods (Tulppo et al., [@B54]). On the contrary to HR variability measurements at rest or few minutes after exercise, rapid and marked changes occurs in both autonomic arms in tens of seconds from sympathetic dominance to restoration of vagal activity resulting decreased HR after exercise (Tulppo et al., [@B52]). The unique behavior of autonomic regulation initially after maximal exercise is the major candidate to explain differences in HR recovery between diabetic and non-diabetic patient groups.

Study limitations
-----------------

The measurements of the present study were performed under continued prescribed medication because of ethical reasons and the well known withdrawal effect of beta-block cessation. However, the present results will have more practical implications when the analyses are performed at a time when the patients are on their normal medication.

Clinical applications
---------------------

Based on the present study, it is important to emphasize the role of physical exercise in maintaining good cardiovascular function, improving physical performance, and losing weight. Although all the patients were on optimized medication, it is important to underscore that behavioral modification, exercises, and diet should be given priority similar to other preventive medications (Chow et al., [@B5]).

Conclusion
==========

Heart rate recovery 1 min after exercise is the most powerful index separating CAD patients with and without T2D in the modern treatment era, beyond short-term HR variability measurements at rest, during exercise, or in post-exercise condition. HR recovery is delayed in CAD + T2D patients compared with CAD patients without T2D, suggesting impairment of vagal activity and/or augmented sympathetic activity after exercise. However, blunted HR recovery initially after exercise in diabetic patients compared with non-diabetic patients is more closely related to exercise capacity and obesity than to T2D itself.
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